Memantine for Liver Cancer and Cirrhosis
This study is looking at how well a drug called memantine (Namenda) works for people with liver cancer (hepatocellular carcinoma) and cirrhosis. You might be able to join if you are 18 or older and have newly diagnosed liver cancer that hasn't been treated before, or if your cancer has returned after surgery or radiation more than two years ago. The study aims to see how long patients live without their cancer getting worse after 6 months of treatment. It also looks at how memantine affects your quality of life. The study plans to enroll 12 participants, but its current status is unclear.
- Study design
- This is a single-site study that plans to enroll 12 participants. It is an interventional study, meaning participants will receive a specific treatment.
- What's involved
- You would take memantine (Namenda) by mouth once daily, starting at 5 mg and increasing up to 20 mg daily.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary endpoint measures progression-free survival at 6 months from the start of treatment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Prospective Study of Memantine in Patients With Cirrhosis and Liver Cancer
At a glance
Conditions
Where it's being run
2 sites across 1 statesStudy leadership
- Arthur Winer, MD · PRINCIPAL_INVESTIGATOR · Inova Health Care Service
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Patients Progression Free Survival at 6 months6 months from the start of treatment
The response and progression will be evaluated by the Response Evaluation Criteria in Solid Tumors (RECIST) guideline version 1.1. The progression of the disease is defined as at least a 20% increase in the sum of the Longest Diameter LD of target lesions, taking the smallest sum LD recorded as reference since the treatment started or the appearance of one or more new lesions or death due to disease without objective evidence of progression.